Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

[1]  Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability , 2019, Clinical pharmacology in drug development.

[2]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[3]  Yaiza Beatriz Molero-Díez,et al.  Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.

[4]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[5]  P. Ridker.  Anti‐inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials , 2018, Journal of internal medicine.

[6]  Jeroen J. Bax,et al.  Fourth universal definition of myocardial infarction (2018). , 2018, European heart journal.

[7]  M. D. Di Carli,et al.  Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.

[8]  Sanjiv J. Shah,et al.  Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF , 2018, European heart journal.

[9]  P. Ridker,et al.  Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond , 2018, Front. Cardiovasc. Med..

[10]  K. Nelander,et al.  Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor , 2018, Clinical and translational science.

[11]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[12]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[13]  N. Eriksson,et al.  P3247Polymorphisms of the ALOX5AP gene (5-lipoxygenase activating protein) are associated with increased cardiovascular risk in patients with acute coronary syndrome: Analysis of PLATO genetics sub-study , 2017 .

[14]  A. Lerman,et al.  Incremental Value of Transthoracic Doppler Echocardiography‐Assessed Coronary Flow Reserve in Patients With Suspected Myocardial Ischemia Undergoing Myocardial Perfusion Scintigraphy , 2017, Journal of the American Heart Association.

[15]  P. Ridker.  How Common Is Residual Inflammatory Risk? , 2017, Circulation research.

[16]  M. Budoff,et al.  Effect of treatment with 5‐lipoxygenase inhibitor VIA‐2291 (atreleuton) on coronary plaque progression: a serial CT angiography study , 2017, Clinical cardiology.

[17]  J. Blomster,et al.  Coronary flow reserve as a link between exercise capacity, cardiac systolic and diastolic function. , 2016, International journal of cardiology.

[18]  C. Weber,et al.  Regulation of atherosclerotic plaque inflammation , 2015, Journal of internal medicine.

[19]  Öjvind Davidsson,et al.  Recent advances for FLAP inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[20]  Nicola Capuano,et al.  Effects of Ranolazine on Noninvasive Coronary Flow Reserve in Patients with Myocardial Ischemia But without Obstructive Coronary Artery Disease , 2015, Echocardiography.

[21]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[22]  Ornella Rimoldi,et al.  Coronary microvascular dysfunction: mechanisms and functional assessment , 2015, Nature Reviews Cardiology.

[23]  Paul M Ridker,et al.  Anti-inflammatory therapies for cardiovascular disease. , 2014, European heart journal.

[24]  N. Frangogiannis,et al.  The inflammatory response in myocardial injury, repair, and remodelling , 2014, Nature Reviews Cardiology.

[25]  T. Lüscher,et al.  Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes , 2013, Journal of cardiovascular medicine.

[26]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[27]  F. Dela,et al.  Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure. , 2013, European heart journal cardiovascular Imaging.

[28]  G. Brandrup-Wognsen,et al.  Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. , 2013, Journal of the American College of Cardiology.

[29]  B. Gersh,et al.  ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology , 2013 .

[30]  C. Gudex,et al.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study , 2012, Quality of Life Research.

[31]  E. Picano,et al.  Coronary flow reserve during dipyridamole stress echocardiography predicts mortality. , 2012, JACC. Cardiovascular imaging.

[32]  R. Blankstein,et al.  Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus , 2012, Circulation.

[33]  R. Blankstein,et al.  Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. , 2012, JACC. Cardiovascular imaging.

[34]  M. Goldacre,et al.  Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010 , 2012, Circulation. Cardiovascular quality and outcomes.

[35]  M. Pfeffer,et al.  Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction , 2011, European journal of heart failure.

[36]  P. Bassett,et al.  Coronary flow reserve assessed by myocardial contrast echocardiography predicts mortality in patients with heart failure. , 2011, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[37]  J. Tardif,et al.  Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome , 2010, Circulation. Cardiovascular imaging.

[38]  Magnus Bäck,et al.  Leukotriene Signaling in Atherosclerosis and Ischemia , 2009, Cardiovascular Drugs and Therapy.

[39]  E. Picano,et al.  The additive prognostic value of wall motion abnormalities and coronary flow reserve during dipyridamole stress echo. , 2006, European heart journal.

[40]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[41]  G. V. von Schulthess,et al.  Beta-adrenergic blockade and myocardial perfusion in coronary artery disease: differential effects in stenotic versus remote myocardial segments. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[43]  S. Cherry,et al.  Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging , 1999, European Journal of Nuclear Medicine.

[44]  L. Dubé,et al.  Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial , 1996 .

[45]  E. Israel,et al.  Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. , 1996, JAMA.

[46]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[47]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.